

Tularik, Inc.

Page 2

York, New York 10285, 212-526-7000; J.P. Morgan & Co., 60 Wall Street, New York, New York 10260, 212-648-8612; Chase H & Q, One Bush Street, San Francisco, California 94104, 415-439-3000; Thomas Weisel Partners LLC, One Montgomery Street, San Francisco, California 94101, 415-364-2500; or Warburg Dillon Read LLC, 229 Park Avenue, New York, New York 10171, 212-821-3000.

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available drugs based on gene regulation. Tularik programs address cancer, CMV, diabetes, obesity, inflammation, allergy/asthma, hypercholesterolemia and bacterial diseases, and a class of targets known as orphan nuclear receptors. Tularik has established strategic partnerships with Japan Tobacco Inc., Roche Bioscience and Knoll AG. For additional information, visit Tularik's Internet website at www.tularik.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

###